



The aryl hydrocarbon receptor nuclear translocator-interacting protein 2 suppresses the estrogen receptor signaling via an Arnt-dependent mechanism

Yanjie Li¹, Yi Li¹, Tianmin Zhang, William K. Chan^{*}

Department of Pharmaceutics and Medicinal Chemistry, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211, USA

ARTICLE INFO

Article history:

Received 10 May 2010
and in revised form 16 July 2010
Available online 29 July 2010

Keywords:

Estrogen receptor
Arnt
Ainp2
Arnt-interacting protein

ABSTRACT

We explored whether modulation of the estrogen receptor (ER) signaling is possible through an aryl hydrocarbon receptor nuclear translocator (Arnt)-dependent mechanism. We utilized the Arnt-interacting protein 2 (Ainp2) to examine whether the presence of Ainp2 in MCF-7 cells would interfere with the Arnt-mediated ER signaling. We found that Arnt increased the 17 beta-estradiol (E2)-dependent luciferase activity and Ainp2 significantly suppressed this Arnt-mediated luciferase activity. Ainp2 significantly suppressed 25% of the E2- and Arnt-dependent up-regulation of the *GREB1* message. No suppression of the ER target gene expression by Ainp2 was detected in Arnt-knockdown MCF-7 cells and in Arnt-independent ER signaling. Although Ainp2 did not interact with ER alpha and ER beta, it suppressed the ER alpha::Arnt interaction and reduced the E2-driven recruitment of Arnt to the *GREB1* promoter. We concluded that Ainp2 suppresses the ER signaling by not allowing Arnt to participate in the ER-dependent, Arnt-mediated activation of gene transcription.

© 2010 Elsevier Inc. All rights reserved.

Introduction

Arnt belongs to the basic-helix-loop-helix-PAS protein family and functions as an essential dimerization partner in the aryl hydrocarbon receptor (AhR)² [1] and the hypoxia inducible factor-1α (HIF-1α) [2] signaling pathways. Upon ligand binding, AhR translocates into the nucleus, dimerizes with Arnt to form the AhR::Arnt heterodimer and in turn up-regulates the transcription of drug metabolizing genes such as *CYP1A1* and *CYP1A2* [3]. Similarly under hypoxia, HIF-1α dimerizes with Arnt and binding of this heterodimer to the HIF-1 response element triggers the up-regulation of the transcription of genes such as *VEGF* [4], *EPO* [5], and several other glycolytic enzymes [6]. Our laboratory is interested in studying the Arnt-dependent signaling pathways. In an effort to identify essential proteins that play a role in these pathways, we used an Arnt construct as the bait to screen for interacting peptides from a human liver cDNA library using the phage display strategy and subsequently identified a novel Arnt-interacting protein Ainp2 [7]. Ainp2 contains 77 amino acids and is expressed predominantly in human liver and Jurkat cells and it enhances the 3-MC-induced expression of *CYP1A1* in HepG2 cells [7].

ER is a member of the steroid receptors which belong to the superfamily of nuclear receptors [8]. These steroid receptors share three homologous domains: the N-terminal transactivation domain, the central DNA-binding domain, and the C-terminal ligand-binding domain [9]. Upon treatment of the ligand E2, the activated ER binds to the estrogen response elements (ERE), followed by activation of target genes such as *pS2* [10], *GREB1* [11], *c-fos* [12], *adrenomedullin* [13], and *cathepsin D* [14]. The overall transcriptional activation of ER-responsive genes requires receptor dimerization, conformational change in the ligand-binding domain [15] and recruitment of coactivators such as the p160 coactivators (SRC-1, SRC-2, and SRC-3) [16–18], PPARBP [19], and the SWI/SNF chromatin remodeling complex [20]. This activation process is understandably complex; abnormal signaling may lead to induction and progression of different cancers including the ER-positive breast cancer [21,22].

Mechanisms for the cross-talk between AhR and ER signaling pathways are complex as well. AhR ligands have been shown to affect the ER signaling through AhR-dependent mechanisms [23,24]. However, activation of the ER signaling by 3-MC – an AhR ligand – has been reported to be AhR independent [25] and it appears that 3-MC is also an ERα ligand [26]. One of these cross-talk mechanisms that involves Arnt can be observed at the *pS2* promoter: Binding of liganded AhR::Arnt heterodimer to the DRE-like motif at –527 to –514 inhibits the ER signaling, possibly by interfering with the binding of the ER homodimer to the ERE [27]. Interestingly, Arnt acts as a potent coactivator for the ER signaling and it interacts with ER through the E2-activated ligand-binding domain [28]. The function of Arnt in the ER signaling may involve the

^{*} Corresponding author. Fax: +1 209 946 2410.

E-mail address: wchan@pacific.edu (W.K. Chan).

¹ These authors contributed equally to this work.

² Abbreviations used: AhR, aryl hydrocarbon receptor; Arnt, aryl hydrocarbon receptor nuclear translocator; E2, 17 beta-estradiol; Ainp2, Arnt-interacting protein 2; HIF-1α, hypoxia inducible factor-1α; 3-MC, 3-methylchloranphrene; ER, estrogen receptor; ERE, estrogen response elements; C_T, cycle threshold; WCL, whole cell lysates; αNF, α-naphthoflavone.

interactions with some other coactivators including p300 [24] and two coiled coil coactivators (TRIP230 and CoCoA) [29]. Here we showed that Ainp2 suppresses both the E2-dependent, ERE-driven luciferase activity and the up-regulation of the *GREB1* gene through an Arnt-dependent mechanism in MCF-7 cells. This Arnt-mediated mechanism reveals a novel approach for developing agents that might be effective for the treatment of the ER-positive breast cancer.

Materials and methods

Cell line and reagents

MCF-7 cells were grown in the media of either Advanced DMEM/F12 (Gibco, Carlsbad, CA) plus 5% HyClone FBS (Thermo Scientific, Waltham, MA) or DMEM (Sigma, St. Louis, MO) plus 10% FBS (Tissue Culture Biologicals, Tulare, CA) which is supplemented with 0.2 mM L-glutaMAX, 100 U/ml penicillin, and 0.1 mg/ml streptomycin. All cell culture reagents were purchased from Invitrogen (Carlsbad, CA) if not specified. Lipofectamine 2000 was purchased from Invitrogen (Carlsbad, CA). Eugene HD was purchased from Roche (Indianapolis, IN). The β -galactosidase plasmid pCH110 was purchased from Amersham Pharmacia (Piscataway, NJ). The pCMV-Tag4 plasmid was purchased from Stratagene (La Jolla, CA). Charcoal dextran-stripped FBS was purchased from Gemini (West Sacramento, CA). The Dual-Light luciferase assay kit was purchased from Applied Biosystems (Foster City, CA). Anti-Arnt rabbit IgG (H-172), anti-ER α mouse IgG (ER1D5), anti-His mouse IgG (sc-8036) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit IgG was purchased from Sigma (St. Louis, MO). Dynabeads protein G and DynaMag-2 magnet were purchased from Invitrogen (Carlsbad, CA). Odyssey blocking buffer and IRDye 800CW conjugated goat anti-mouse IgG were purchased from LI-COR Biosciences (Lincoln, NE). The pCMV-Tag4-Ainp2 plasmid was generated by cloning the Ainp2 cDNA into the BamHI/XhoI sites of the pCMV-Tag4 plasmid. The pCMV-GST plasmid was generated by amplifying the GST cDNA from the pET42b plasmid (EMD Biosciences Novagen, Gibbstown, NJ) and then inserting the cDNA into the EcoRI/HindIII sites of the pCMV-Tag4 plasmid. The pCMV-Tag4-GST-Ainp2 plasmid was generated by amplifying the Ainp2 cDNA and then inserting the cDNA into the BamHI/XhoI sites of the pCMV-Tag4-GST plasmid. Protein concentrations were determined by the BCA assay (Pierce, Rockford, IL). IRDye700-conjugated ERE (OL489, 5'-IRD700/GGATCTAGTCACTGTGACCCCGATC-3'; OL490, 5'-IRD700/GATCCGGGGTCACAGTGACCTAGATCC-3') and IRDye700-conjugated DRE (OL439, 5'-IRD700/TCGAGTAGATCAGCAATGGGCCCCAGC-3'; OL440, 5'-IRD700/TCGAGCTGGGCCCCATTGCGTGATCTAC-3') were purchased from Integrated DNA Technologies (San Diego, CA).

Luciferase assay

Either Eugene HD or Lipofectamine 2000 was used in our transfection experiments. For studies using Lipofectamine 2000, MCF-7 cells were grown to 90% confluence in a 24-well plate. For each well, the cells were incubated with a transfection mixture of 200 μ l of OPTI-MEM containing Lipofectamine 2000 (2 μ l/well) and various plasmids (0.2 μ g of pVit-ERE-Luc, 25 ng of pCH110, 1 μ g of pCMV-Tag4 or pCMV-Tag4-Ainp2) at 37 °C. After 5 h, the wells were washed HyQ HBSS twice and then incubated with 1 ml of phenol red-free DMEM/F12 supplemented with 10% charcoal dextran-stripped FBS and 0.2 mM L-glutaMAX in the presence of 10 nM E2 or vehicle (80% ethanol/20% DMSO) at 37 °C for 18 h. The luciferase assay was then performed using the Dual-Light kit as described previously [7]. For studies using Eugene HD, MCF-7 cells were pre-treated for 48 h in phenol red-free DMEM complete

media with 10% charcoal dextran-stripped FBS before being seeded in a 24-well plate (10⁵ cells/well). On the next day, cells (about 85% confluent) were transfected with 1 μ g of plasmids/2.5 μ l Eugene HD/well. Plasmids contained 50 ng of the pVit-ERE-Luc reporter plasmid, 25 ng of the β -gal plasmid pCH110, and 925 ng of various plasmid combinations. After 24 h, cells were treated with either 10 nM E2 or vehicle (80% ethanol/20% DMSO) in phenol red-free media with no FBS for another 24 h before being harvested for luciferase assay using the Dual-Light kit. Each of the luciferase activity was normalized by the corresponding β -galactosidase activity.

Real-time qPCR

MCF-7 cells were grown to 90% confluence in a 6-well plate. A transfection mixture of 500 μ l of OPTI-MEM containing Lipofectamine 2000 (6 μ l) and a plasmid (4 μ g, pCMV-Tag4, pCMV-Tag4-Ainp2, pSport or pSport-Arnt) was added to each well, followed by an incubation at 37 °C for 5 h. After that, the wells were washed with HyQ HBSS twice and then incubated with 2 ml of phenol red-free DMEM/F12 supplemented with 10% charcoal dextran-stripped FBS and 0.2 mM L-glutamate in the presence of 10 nM E2 or vehicle (80% ethanol/20% DMSO) at 37 °C for 18 h. After induction, the total RNA was isolated using the MasterPure kit (Epicentre, Madison, WI). Reverse transcription was performed using 1 μ g of RNA and MMLV reverse transcriptase (Epicentre, Madison, WI) in a 50 μ l reaction where 2 μ l of that reaction mix was then used for real-time qPCR using the SYBR Green FailSafe kit (Epicentre, Madison, WI) and an Opticon II Real-time PCR Detection System (MJ Research) as previously published [7]. The PCR conditions were as follows (see Table 1 for primer sequences): for pS2/18S (35 cycles): 30 s at 94 °C, 30 s at 49 °C for pS2 and 55 °C for 18S, then 45 s at 70 °C; for GREB1/18S (35 cycles): 30 s at 94 °C, 30 s at 54 °C for pS2 and 55 °C for 18S, then 45 s at 70 °C. The final PCR products were also analyzed by agarose gel electrophoresis. Relative abundance of the pS2 or GREB1 transcript was determined by the cycle threshold (C_T) according to the equation and normalized to the 18S standard.

TALON co-precipitation assay

Full-length cDNA sequences of ER α and ER β were amplified by PCR from the plasmids pAC_{sk12}CMV5-ER α and pAC_{sk12}CMV5-ER β , respectively, and then cloned in the pCMV-Tag4 plasmid for the ³⁵S expression of ER α and ER β in the rabbit reticulocyte lysate (Promega, Madison, WI). The reticulocyte lysate expressed ³⁵S-ER α , ³⁵S-ER β or ³⁵S-Arnt (10 μ l) was rotated in 800 μ l of the co-precipitation buffer (50 mM HEPES, pH 7.4, containing 10% glycerol and 150 mM KCl) with 30 μ l of the TALON resin (BD Biosciences Clontech, Mountain View, CA) and 1 mg of BSA in the presence or

Table 1

Sequence-specific PCR primers used for SYBR Green real-time qPCR and chromatin immunoprecipitation experiments.

Arnt sense (OL144)	5'-GAATTGGACATGGTACCAGG-3'
Arnt antisense (OL145)	5'-AAGCTGATGGCTGGACAATG-3'
GREB1 sense (OL213)	5'-CAAAGAATAACCTGTTGGCCCTGC-3'
GREB1 antisense (OL214)	5'-GACATGCCTCGGCTCTCATACTTA-3'
pS2 sense (OL196)	5'-GCCAGACAGAGACGTGTACA-3'
pS2 antisense (OL197)	5'-TCACACTCCTCTCTGGAGGG-3'
18S sense (OL96)	5'-CGCCCCCTCGATGCTCTTAG-3'
18S antisense (OL97)	5'-CGGCGGGTCATGGGAATAAC-3'
ERE3 sense (OL437)	5'-TGTGCTCAGTGACCCCTGTG-3'
ERE3 antisense (OL438)	5'-CTGCCCAACAACCTGAAAGA-3'
GST-Ainp2 sense (OL480)	5'-TGGCAAGCCACGTTTGGT-3'
GST-Ainp2 antisense (OL481)	5'-CTGAAAGCA AGATTTTCAG-3'

absence of 150 μ l (15 μ g) of the TALON-purified baculovirus expressed 6His-Ainp2 [7] at 32 rpm at 4 °C for 2 h. After incubation, the resin was washed four times with 1 ml of the wash buffer (50 mM HEPES at pH 7.4 containing 10% glycerol, 150 mM KCl, 10 mM β -mercaptoethanol and 5 mM imidazole) and then eluted with 30 μ l of the SDS-PAGE sample buffer. The samples were separated on a 10% SDS-PAGE gel. After the gel was dried, the 35 S-labeled proteins were analyzed by autoradiography.

Gel shift assay

MCF-7 cells were pre-treated for 48 h in phenol red-free DMEM complete media with 10% charcoal dextran-stripped FBS, followed by either E2 or vehicle treatment for 45 min before harvest. Nuclear extracts were prepared according to a published protocol [30]. Gel shift assay was performed as follows: Gel shift buffer (25 mM HEPES, pH 7.4, 1 mM EDTA, 1 mM DTT, 10% glycerol, 0.1 M KCl) was added to the MCF-7 nuclear extracts (3 μ g) in the presence or absence of additional proteins (e.g. baculovirus expressed Arnt or Ainp2) to a final volume of 13 μ l. Poly-dIdC (3 μ g, 1 μ l) was then added. After 20 min at room temperature, IRDye700-conjugated ERE (0.5 pmol, 2 μ l) was added. In some cases, IgG was added before the ERE probe addition, followed by an additional 10 min incubation at room temperature. After 20 min at room temperature, 10 $\times$ orange loading dye (LI-COR, Lincoln, NE) was added before the samples were resolved on a 5% native acrylamide gel (1XTBE) at 4 °C (185 volts) for 2 h. After that, the gel was immediately analyzed using a LI-COR Odyssey imaging system. AhR gel shift assay using baculovirus expressed AhR and Arnt were performed as described previously [Luu, 2008 #1644], except that IRDye700-conjugated DRE (0.5 pmol, 2 μ l) was used instead of the 32 P probe. For lanes 1–4 in Fig. 3C, Dynabeads protein G (2 μ l, 10 min on ice) was added after the IgG incubation step to remove the IgG from the gel shift samples before addition of the IRDye700 ERE probe.

RNA interference studies

MCF-7 cells were grown in a 6-well plate to 30–50% confluence before transfection. Each well was transfected with 160 pmol of human Arnt siRNA (sc-29733, Santa Cruz Biotechnology, Santa Cruz, CA) using Lipofectamine 2000 (6 μ l) according to the manufacturer's protocol. After 48 h, the total RNAs were extracted and subsequent RT-qPCR was performed as described above. PCR reactions were performed as follows: 35 cycles of 30 s at 94 °C, 30 s at 50 °C for Arnt and 55 °C for 18S, then 45 s at 70 °C. To study the effects of Ainp2 under the Arnt-knockdown condition, MCF-7 cells were grown to 50% confluence in a 24-well plate. To each well, a transfection mixture which contained 200 μ l of OPTI-MEM I containing Lipofectamine 2000 (2 μ l), various plasmids (0.2 μ g of pERE-Luc, 25 ng of pCH110, and 1 μ g of pCMV-Tag4 or pCMV-Tag4-Ainp2) and 20 pmol of human Arnt siRNA or human integrin α 4 siRNA (sc-35685, Santa Cruz Biotechnology, Santa Cruz, CA) was added. After 5 h, cells were washed with HyQ HBSS twice and then incubated with 1 ml of phenol red-free DMEM/F12 supplemented with 5% charcoal dextran-stripped FBS and 0.2 mM L-glutamate. After 25 h, cells were treated with 10 nM E2 or vehicle (80% ethanol/20% DMSO) for another 18 h at 37 °C, followed by the luciferase assay as described above.

Co-immunoprecipitation assay

MCF-7 cells were pre-treated for 48 h in phenol red-free DMEM supplemented with 10% charcoal dextran-stripped FBS. After that, cells were treated with 10 nM E2 or vehicle (80% ethanol/20% DMSO) for 24 h at 37 °C. Cells were harvested by resuspending the cells in the lysis buffer (25 mM HEPES, pH 7.4, 1 mM EDTA,

1 mM DTT, 10% glycerol, 0.4 M KCl, 2 μ g/ml of leupeptin, and 1 mM PMSF). After three freeze-thaw cycles, the samples were centrifuged at 16,000g for 10 min at 4 °C. The KCl concentration was adjusted to 0.2 M final concentration. The supernatants were the whole cell lysates (WCL) and used for co-immunoprecipitation experiments as follows: MCF-7 WCL (100 μ g) were incubated in the presence or absence of other proteins (e.g. 50 μ g of TALON-purified baculovirus expressed Ainp2 [7] or Sf9 lysate) at 30 °C for 30 min. Anti-Arnt rabbit IgG H-172 (10 μ l) or rabbit IgG was then added. After 30 min at room temperature, 10 μ l of Dynabeads protein G was added to the samples. The resulting suspension was rotated at 4 °C for 1 h. With the use of a DynaMag-2 magnet, supernatants were separated and discarded. The beads were then washed with 0.6 ml of the wash buffer (25 mM HEPES, pH 7.4, 1 mM EDTA, 1 mM DTT, 10% glycerol and 0.1% Tween-20) four times with 5 min rotation at 4 °C between each wash. After washing, proteins were eluted from the beads using 20 μ l of SDS-PAGE sample buffer. Quantitative Western analysis using a LI-COR Odyssey near infrared imaging system was performed to quantify the co-immunoprecipitated ER α protein.

Quantitative Western analysis

After SDS-PAGE, protein was transferred onto a nitrocellulose membrane using Bio-Rad mini trans-Blot cell for 1.5 h at 4 °C. Membrane was blocked with the Odyssey blocking buffer for 1 h and incubated with anti-ER α mouse IgG (ER1D5, 1:500) overnight at 4 °C in the blocking buffer containing 0.1% Tween-20. The membrane was then washed four times with 1XPBS plus 0.1% Tween-20 (5 min per wash) at room temperature. The washed membrane was then incubated with IRDye800CW-conjugated goat anti-mouse (1:5000) in the blocking buffer containing 0.1% Tween-20 for 1 h at room temperature in the dark. The membrane was washed four times as described above and then analyzed by a LI-COR Odyssey near infrared imaging system.

Chromatin Immunoprecipitation assay

MCF-7 cells were grown in phenol red-free DMEM containing 10% of charcoal dextran-stripped FBS for 48 h before experiment. The plasmid (pCMV-GST or pCMV-GST-Ainp2, 20 μ g) was introduced into MCF-7 cells (4×10^6 cells in 0.4 ml of DMEM containing 2.5% of charcoal dextran-stripped FBS) using a BTX ECM 830 electroporator which was set at LV mode, 160 volts for 70 ms. After 48 h on a 100 mm plate at 37 °C, cells were treated with either 10 nM E2 or vehicle (80% ethanol/20% DMSO) for 45 min at 37 °C. After that, cells were cross-linked with 1% formaldehyde in phenol red-free DMEM for 10 min at room temperature. Glycine (125 mM final concentration) was added to quench the reaction. After 10 min at room temperature, cell pellet was harvested, resuspended in lysis buffer (120 μ l, 50 mM Tris, pH 8.1, containing 10 mM EDTA, 1% SDS) containing protease inhibitors PMSF (1 mM) and leupeptin (2 μ g/ml), and then sonicated in a circulating ice water bath using a Misonix S4000 sonicator equipped with a cuphorn. The sonication setting was as follows: 40% output, 10 s on/15 s off for 15 times. The sonicated cell lysis was centrifuged at 16,000g for 10 min at 4 °C. The resulting supernatant was diluted ten times into the dilution buffer (20 mM Tris, pH 8.1, containing 2 mM EDTA, 1% Triton X-100, 150 mM NaCl) containing protease inhibitors (1 mM PMSF and 2 μ g/ml of leupeptin) to become the sample for chromatin co-immunoprecipitation assay and an aliquot (50 μ l) was set aside as the input. Each sample (1 ml) was pre-cleared with Dynabeads Protein G (3 μ l) containing sheared salmon sperm DNA (1 μ g) and rabbit serum (2.5 μ l, Sigma R9133) by rotating for 2 h at 4 °C. The pre-cleared supernatant was transferred to a tube containing Dynabeads Protein G (10 μ l)

pre-incubated with anti-Arnt IgG (0.5 μ l) for 1 h at 4 °C. After rotating overnight at 4 °C, the pellet was obtained using a DynaMag-2 magnet and then washed sequentially with Buffer I (dilution buffer plus 0.1% SDS), Buffer II (Buffer I except 500 mM NaCl), Buffer III (10 mM Tris, pH 8.1, 1 mM EDTA, 250 mM LiCl, 1% NP40 and 1% deoxycholate), and two times with 10 mM Tris, pH 8, and 1 mM EDTA. Each wash involved 10 min rotation at 4 °C. The washed pellet was resuspended into the elution buffer (50 μ l, 0.1 M NaHCO₃ and 1% SDS). The resuspended sample (and also the input) was heated at 65 °C for 7 h to reverse cross-linking. The resulting sample was treated with RNaseA (0.5 μ l of 10 mg/ml) for 30 min at 37 °C, followed by proteinase K treatment (0.15 μ l of 50 mg/ml of proteinase K, 0.65 μ l of 0.5 M EDTA, and 1.3 μ l of 1 M Tris, pH 6.5) for 2 h at 45 °C. DNA was then purified using a Promega Wizard SV gel clean-up kit. PCR was performed using an ERE3-specific primer set ([31], see Table 1 for primer sequences) and a Perkin Elmer GeneAmp 2400 cyclor with the following protocol: 94 °C for 2 min, followed by 40 cycles of 94 °C for 30 s, 58 °C for 30 s, and 72 °C for 30 s. PCR products were visualized and quantified using a LI-COR Odyssey near infrared imaging system after staining the DNA with Syto 60 (LI-COR Biosciences, Lincoln, NE).

Extract preparation

To determine the Arnt content in nuclear extracts, MCF-7 cells were grown to 90% confluence in a 6-well plate before harvest. The washed cell pellets were resuspended into 100 μ l of the cell lysis buffer (25 mM HEPES at pH 7.4 containing 1 mM EDTA, 1 mM DTT, 10% glycerol, 2 μ g/ml of leupeptin and 0.5 mM PMSF). After three times of the freeze/thaw cycle, the cell suspension was centrifuged at 16,000g for 30 min. The pellet was then resuspended in 100 μ l of the same lysis buffer containing 0.4 M KCl. After on ice for 30 min, the cell suspension was centrifuged at 16,000g for 30 min and the supernatant was the nuclear extract. Soluble extracts from Jurkat and MCF-7 cells were prepared using the CytoBuster reagent (Novagen) according to our published protocol [7]. Lumi-Phos WB chemiluminescent substrate (Pierce, Rockford, IL) was used to detect the Western signals.

Statistic analysis

We performed unpaired two-tailed *t* test using the GraphPad Prism 5 software. Statistically significant data were highlighted by the symbol * ($p \leq 0.05$) or ** ($p \leq 0.005$) whereas statistically insignificant data were highlighted by the symbol † ($p > 0.05$).

Results

Effect of Arnt and Ainp2 on the E2-induced, ERE-driven luciferase activity

After 10 nM E2 treatment, Arnt increased the luciferase activity by up to 5-fold in a dose-dependent manner (Fig. 1A). This observed enhancement by Arnt was statistically significant and was consistent with the literature that Arnt is a coactivator in the ER signaling [28]. To examine whether Ainp2 would affect this Arnt effect on the ER signaling, we transiently co-transfected the Ainp2 plasmid with the Arnt plasmid into MCF-7 cells and observed the change in the luciferase activity. The results showed that the enhancement effect of Arnt on the E2-dependent luciferase activity was significantly suppressed in the presence of Ainp2 (Fig. 1B). We noticed that the fold-increase by the Arnt transfection was less in Fig. 1B when compared to the data in Fig. 1A. We suspected that the differences were likely contributed by having different combinations of plasmids transfected. In the absence of the transfected




Fig. 1. Effect of Arnt and Ainp2 on the ER-mediated luciferase activity in MCF-7 cells. (A) Dose-dependent effect of Arnt. Transient transfection was performed using Fugene HD. Each condition was ± 10 nM E2 and the same amount of transfected plasmid (pSport and/or pSport-Arnt). Error bars represent the standard deviation of the means ($n = 3$, means $\pm$ SD). This experiment was repeated at least once with similar results. (B) Ainp2 suppressed the Arnt-dependent luciferase activity. Transient transfection was performed using Fugene HD. Each condition was ± 10 nM E2 and the same amount of transfected plasmids of different combinations (pSport, pSport-Arnt, pCMV-Tag4, pCMV-Tag4-Ainp2). Error bars represent the standard deviation of the means ($n = 3$, means $\pm$ SD). This experiment was repeated at least once with similar results. (C) Ainp2 suppressed the 10 nM E2-driven luciferase activity. Transient transfection was performed using Lipofectamine 2000. 1 μ g of pCMV-Tag4 or pCMV-Tag4-Ainp2 plasmid was transfected. Error bars represent the standard deviation of the means ($n = 6$, means $\pm$ SD). * $p \leq 0.05$, ** $p \leq 0.005$.

Arnt, Ainp2 also suppressed the E2-driven luciferase activity significantly (about 50%) when 1 μ g of the Ainp2 plasmid was transfected (Fig. 1C), suggesting that the endogenous Arnt may play a significant role in the E2-driven luciferase expression in MCF-7 cells. In contrast, the luciferase activities in the presence of the

Ainp2 plasmid were more than that of the plasmid control (Fig. 1B). This observation was probably due to inadequate Ainp2 expression to suppress the Arnt effect from transient transfection.

Effect of Ainp2 on ER target gene expression

We examined the effect of Arnt and Ainp2 on the E2 induction of two ER target genes (*GREB1* and *pS2*) in MCF-7 cells. We found that treatment of 10 nM E2 strongly increased the *GREB1* message by about 9-fold; in the presence of Arnt, this induction was further enhanced significantly by 52% and Ainp2 significantly suppressed the E2-induced *GREB1* message by 25% (Fig. 2A and B). In the case of the *pS2* regulation, however, treatment of 10 nM E2 only up-regulated the *pS2* message by 1.8- to 2.4-fold in MCF-7 cells, depending on which empty plasmid was transfected. Moreover, we failed to observe any change in *pS2* expression when cells were transfected with either Arnt or Ainp2 (Fig. 2C and D), suggesting that the Ainp2 effect on the ER signaling is Arnt-mediated.

Ainp2 interacts with Arnt but not ER α and ER β

To examine whether the suppressive effect of Ainp2 on the ER signaling is mediated through the Ainp2::ER interaction, we investigated whether Ainp2 would interact directly with ER α and ER β . TALON co-precipitation experiments using the TALON-purified baculovirus expressed 6His-Ainp2 as the bait were performed with in vitro expressed 35 S-labeled ER α , ER β , and Arnt. 6His-Ainp2 co-

precipitated the 35 S-labeled Arnt (8.5% of the starting 35 S-Arnt content) whereas no Arnt was detected in the absence of the bait (Fig. 3A, lanes 7–9). These results were consistent with our previous data that Ainp2 interacts with an Arnt construct C Δ 418 in vitro and in HepG2 cells [7]. In contrast, only minimal amounts of 35 S-ER α and 35 S-ER β were detected in the precipitated samples and these precipitated ER bands were not Ainp2-dependent (Fig. 3A, lanes 1–6), showing that Ainp2 does not directly interact with ER α and ER β .

Ainp2 interferes with the Arnt::ER interaction

Next, we examined whether Ainp2 would interfere with the interaction between Arnt and ER α , realizing that both ER α and Ainp2 interact with Arnt. By performing co-immunoprecipitation experiments, we found that Ainp2 suppressed about 50% of the interaction between Arnt and ER α in the presence or absence of E2 (Fig. 3B). Since Ainp2 used in these experiments was the baculovirus 6His-Ainp2 which was affinity purified using the TALON resin from Sf9 lysate, many Sf9 proteins were co-purified with the Ainp2 protein. To rule out the possibility that the interference of the Arnt::ER α interaction was caused by Sf9 proteins, we performed the co-immunoprecipitation experiment in the presence of the Sf9 lysate. We found that the Sf9 lysate did not interfere with the Arnt::ER α interaction. Rabbit IgG co-precipitated ER α to a much lesser extent, suggesting that the co-precipitation of ER α was Arnt-specific. We concluded that Ainp2 competes with ER α




Fig. 2. Effects of Arnt and Ainp2 on the E2 induction of the *GREB1* and *pS2* messages in MCF-7 cells. RT/real-time qPCR showing that Arnt up-regulated (A) and Ainp2 down-regulated (B) the E2-induced *GREB1* message and Arnt (C) and Ainp2 (D) did not affect the E2-induced *pS2* message. All the messages were normalized by the internal standard 18S. A plasmid (pSport, pSport-Arnt, pCMV-Tag4 or pCMV-Tag4-Ainp2) was transfected into the MCF-7 cells. Error bars represent the standard deviation of the means (A and B, $n = 4$; C and D, $n = 2$; means $\pm$ SD). All experiments in this figure were performed in 6-well plates and the final PCR products of 18S (376 bp), *GREB1* (172 bp) and *pS2* (173 bp) are shown. * $p \leq 0.05$, ** $p \leq 0.005$.




Fig. 3. The Ainp2 effect is mediated through Arnt, but not ERα and AhR. (A) TALON co-precipitation assay showing that Ainp2 interacted with Arnt but not ERα and ERβ. The arrows indicate the ^{35}S -ERα (lanes 1–3), ^{35}S -ERβ (lanes 4–6) and ^{35}S -Arnt (lanes 7–9) precipitated in the presence (+) or absence (–) of the baculovirus expressed 6His-Ainp2. This experiment was repeated once with similar results. (B) Ainp2 suppressed the co-immunoprecipitation of ERα using anti-Arnt rabbit IgG (H-172) in MCF-7 whole cell lysates (WCL). The co-precipitated samples were reconstituted $\pm$ baculovirus expressed 6His-Ainp2 $\pm$ Sf9 lysate. Relative precipitated ERα content was calculated by normalizing with the 5% of the starting MCF-7 WCL (5% input). The condition of rabbit IgG in place of anti-Arnt IgG was the negative control. The above images were a representative of the triplicate data. Error bars represent the standard deviation of the means ($n = 3$, means $\pm$ SD). ** $p \leq 0.005$, * $p > 0.05$ (not significant). This experiment was repeated at least once with similar results. (C) Ainp2 did not affect the ER/ERE gel shift complex formation. MCF-7 nuclear extract (3 μg) treated with E2 (lanes 2–4, 6–10) or vehicle (lanes 1 and 5) was used. Lanes 1–2 and 5–6 were identical conditions $\pm$ E2 of two different gel shift experiments, except that lanes 1–2 were treated with Dynabeads protein G. Lanes 11–14 contained baculovirus expressed AhR (1 μl) and Arnt (0.1 μl) and Sf9 soluble extract (5 μg) $\pm$ 10 μM β -naphthoflavone (β NF). Different additions to the gel shift samples are as follows: lane 3, mouse anti-His IgG (5 μl); lane 4, mouse anti-ERα IgG (5 μl); lane 7, rabbit anti-Arnt IgG (1 μl); lane 8, rabbit IgG (1 μl); lane 9, baculovirus expressed TALON-purified Arnt (1 μl); lane 10, baculovirus expressed TALON-purified Ainp2 (1 μl); lane 13, rabbit IgG (1 μl); lane 14, rabbit anti-Arnt IgG (1 μl). The upper arrow shows the ER/ERE complex or AhR/Arnt/DRE complex whereas the lower arrow show the unbound IRDye700-conjugated ERE or DRE probe. Three gel shift experiments were combined in this figure (lanes 1–4, 5–10, 11–14). These gel shift assays were performed multiple times with similar results. (D) Transient transfection results showing that α -naphthoflavone did not alter the ER-dependent luciferase expression $\pm$ Ainp2. Samples, $\pm$ 10 nM E2 treatment, were transfected with the same amount of plasmids of different combinations (pCMV-Tag4-GST/pCMV-Tag4-GST-Ainp2 plasmid of 925 ng total). Transient transfection was performed using Fugene HD. Error bars represent the standard deviation of the means ($n = 3$, means $\pm$ SD). * $p \leq 0.05$, * $p > 0.05$ (not significant).

for Arnt binding and the presence of Ainp2 suppresses the interaction between ERα and Arnt.

Ainp2 does not alter the binding of ERα to ERE in vitro

We performed non-radioactive gel shift assay using near infrared dye (IRDye700) conjugated probe to examine whether Ainp2 would affect the binding of the ERα homodimer to the ERE. We prepared MCF-7 nuclear extracts and observed the E2-dependent gel shift complex (Fig. 3C, lanes 1–2, 5–6). This complex contained ERα but not Arnt because the mouse anti-ERα IgG abolished this complex whereas the rabbit anti-Arnt IgG did not have any effect (lanes 2–4, 6–8). We showed that the same amount of the rabbit anti-Arnt IgG abolished the Arnt-containing AhR gel shift complex (lanes 12–14), confirming that there must not be any Arnt presence in the ER/ERE gel shift complex. Addition of Arnt (10-fold of the

amount used for the AhR gel shift complex formation) to the ER gel shift sample did not alter significantly the complex intensity, suggesting that Arnt does not involve in the formation of the ERα/ERE complex (lanes 6 and 9). In addition, Ainp2 did not change the ERα/ERE complex (lanes 6 and 10), suggesting that Ainp2 does not affect the binding of ERα to the ERE enhancer.

Suppression of the ER-dependent luciferase expression by Ainp2 is not AhR-dependent

We used α -naphthoflavone (α NF) to block the AhR function in MCF-7 cells to address whether AhR is involved in the Ainp2 effect. Transient transfection results showed that 10 μM α NF did not significantly change the E2-activated, ERE-driven luciferase activity (Fig. 3D). In the presence of Ainp2 (925 ng of the transfected Ainp2 plasmid), the luciferase activity was suppressed significantly by

36%, regardless of the presence or absence of α NF, suggesting that AhR does not play a role in the observed suppression of the ER activity by Ainp2.

Suppression of the ER signaling by Ainp2 is Arnt-dependent

We employed RNA interference to decrease the endogenous Arnt message in MCF-7 cells and re-assessed the effect of Ainp2 on the ER signaling in transient transfection studies. MCF-7 cells were transfected with the siRNA specific to the human Arnt, followed by RT/real-time qPCR and Western analysis to examine the Arnt expression. As we compared the Arnt message between the wild-type and Arnt-knockdown MCF-7 cells, the Arnt message in the Arnt-knockdown cells was decreased by 46% (Fig. 4A) whereas the Arnt protein was undetectable by our chemiluminescent Western analysis (Fig. 4B). The human integrin $\alpha 4$ siRNA was used as the negative control since the integrin $\alpha 4$ message was not detectable in the wild-type MCF-7 cells by RT-PCR (data not shown). Data from the luciferase assay showed that treatment with the Arnt siRNA reduced the E2-activated luciferase activity significantly by about 64% (Fig. 4C, lanes 1 and 3). This effect should be Arnt-specific since there was no significant decrease of the luciferase activity when the integrin $\alpha 4$ siRNA was used (Fig. 4C, lanes 1 and 2). When we transfected the Ainp2 plasmid (1 μ g) into the wild-type cells, the luciferase activity was suppressed by 42% (Fig. 4C, lanes 1 and 4). When we transfected the Ainp2 plasmid into the Arnt-knockdown cells, Ainp2 could no longer cause a statistically significant change in the luciferase activity (Fig. 4C, lanes 3 and 5). In addition, suppression of the luciferase activity by Ainp2 was essentially the same between the wild-type and Arnt-knockdown cells (Fig. 4C, lanes 4 and 5). These data supported that this Ainp2 effect is Arnt-dependent.

Ainp2 suppresses the recruitment of Arnt to the GREB1 promoter

It has been reported that Arnt is recruited to the ERE promoter after E2 treatment and acts as a coactivator [28]. This recruitment likely involves the interaction between ER and Arnt. Realizing that Ainp2 suppresses the Arnt::ER α interaction, we examined whether Ainp2 would inhibit the recruitment of Arnt to an ER-dependent promoter. We used GST-Ainp2 for this study because GST can be used as the negative control, which should be expressed similarly as the GST-Ainp2 fusion protein in MCF-7 cells after transfection. First, we confirmed that GST-Ainp2 was capable of suppressing the Arnt-mediated, E2-driven luciferase activity. We found that GST-Ainp2 suppressed the Arnt-mediated luciferase activity even more so than that of Ainp2, although the fold induction by E2 was less in the presence of GST (Figs. 5A and 1B). Next, we performed chromatin immunoprecipitation experiments using MCF-7 cells that were either wild-type or had undergone transient transfection with a plasmid expressing GST-Ainp2 or GST. Using a primer set which selectively amplifies the GST-Ainp2 junction, we observed the expression of the GST-Ainp2 message in MCF-7 cells after transient transfection (Fig. 5B). The chromatin immunoprecipitation results showed that Arnt recruitment by E2 to the ERE3 region of the GREB1 promoter was significantly suppressed by about 50% in the presence of GST-Ainp2 but not GST (Fig. 5C), strongly suggesting that suppression of the Arnt recruitment by Ainp2 leads to reduction of the ER-dependent activation of the GREB1 gene transcription.

Discussion and conclusions

Prior to testing out our hypothesis that Ainp2 may modulate the ER signaling via an Arnt-dependent mechanism, we made certain




Fig. 4. Effect of Ainp2 on the E2-activated, ER-mediated luciferase activity in Arnt-knockdown MCF-7 cells. (A) RT/real-time qPCR showing a decrease of the endogenous Arnt message after transfection of 160 nM Arnt siRNA. Error bar represents the standard deviation of the means ($n = 2$, means $\pm$ SD) of the amount of Arnt normalized to the corresponding 18S. (B) Chemiluminescent (Lumi-Phos) Western analysis showing the reduced expression of the Arnt protein after gene silencing. 10 μ g of nuclear extracts was separated on a 10% SDS-PAGE gel, followed by the Western blot using the anti-Arnt antibodies (sc-8077, Santa Cruz, 1:500). The arrow indicates the Arnt protein. (C) Luciferase assay showing that the Ainp2 effect in the E2-activated ER signaling was Arnt-dependent. Transient transfection was performed using Lipofectamine 2000. All conditions contained 10 nM E2 and the same amount of transfected plasmids of different combinations (pCMV-Tag4 or pCMV-Tag4-Ainp2). The normalized luciferase activity of the empty vector (pCMV-Tag4) was arbitrarily set as 1 and used to calculate the relative luciferase activity. All conditions were performed in six replicates ($n = 6$) except for the control ($n = 12$). ** $p < 0.005$, * $p > 0.05$ (not significant).

that Arnt is involved in the ER signaling in MCF-7 cells. When we transfected Arnt into MCF-7 cells, we observed up to 5-fold increase in the E2-dependent, ERE-driven luciferase activity. This luciferase activity was suppressed by more than 50% when the Arnt gene was silenced. These data revealed that Arnt plays a role in the ER-dependent activation of gene transcription in MCF-7 cells, consistent with the data in the literature showing that Arnt is a coactivator in the ER signaling pathway. This Arnt effect appears to be




Fig. 5. Effect of GST-Ainp2 on the E2-mediated recruitment of Arnt to the *GREB1* promoter in MCF-7 cells. (A) Luciferase activity of samples $\pm$ E2 treatment and transfected with the same amount of plasmids of different combinations (pSport/pSport-Arnt plasmid of 500 ng total and pCMV-Tag4-GST/pCMV-Tag4-GST-Ainp2 plasmid of 425 ng total). Transient transfection was performed using Fugene HD. Error bars represent the standard deviation of the means ($n = 3$, means $\pm$ SD). ** $p \leq 0.005$, * $p > 0.05$ (not significant). (B) Agarose gel images of the RT-PCR data showing the presence of the GST-Ainp2 transcript in pCMV-Tag4-GST-Ainp2 transfected (right) MCF-7 cells but not in wild-type (WT, left) and pCMV-Tag4-GST transfected (middle) MCF-7 cells. PCR primers (OL480 and 481) were used to amplify a region spanning the GST-Ainp2 junction (240 bp). (C) ChIP data using the wild-type and transfected MCF-7 cells (as shown in B) to show the suppression of the E2-driven Arnt recruitment to the *GREB1* promoter by GST-Ainp2. The upper part is an example of agarose gel images showing the amplified ERE3 region of the *GREB1* promoter (168 bp) under various conditions. 5% input represents the PCR product using 5% of the starting lysate as the template. Error bars represent the standard deviation of the means ($n = 3$, means $\pm$ SD). * $p \leq 0.05$.

gene-specific: Although Arnt was not recruited to the *pS2* and *c-fos* promoters in MCF-7 cells [24], Arnt was capable of up-regulating the *GREB1* message in these cells (Fig. 2A). Moreover, the recruitment of Arnt to the ER promoter regions appears to be cell-specific: Arnt was found in the *pS2* promoter of T47 [28] but not MCF-7 cells [24]. Since Arnt is not recruited to the *pS2* promoter in MCF-7 cells,

it is not surprising that transfection of Arnt into this cell line did not alter the *pS2* message (Fig. 2C).

We hypothesized that since Ainp2 interacts with Arnt, it should affect the Arnt function in the ER signaling. This hypothesis is consistent with the literature that activation of Arnt-dependent pathways (such as AhR and HIF-1 α) and down-regulation of the Arnt protein expression suppress the ER-mediated transcriptional activity [32], although the nuclear Arnt content seems abundant in mouse and rat hepatoma cells [33]. Indeed the transfected Ainp2 suppressed the E2-activated, ERE-driven luciferase activity in MCF-7 cells. Our mechanistic studies supported that this Ainp2 effect is mediated through Arnt. Events that are not Arnt-dependent, such as binding of the ER α homodimer to the ERE and up-regulation of the *pS2* message by E2, were not affected by Ainp2. In principle, the ligand-bound AhR and HIF-1 α in MCF-7 cells may play a role in this Ainp2 effect since they all interact with Arnt. Interestingly, the ligand-bound AhR, which is part of the cullin 4B ubiquitin ligase complex, promotes the polyubiquitination of ER α and in turn reduces the ER α protein level [34]; this AhR action potentially synergizes the Ainp2 suppression of the ER α function. In this paper, we have strategically addressed the Ainp2 effect on the ER signaling under conditions whereby the amount of the liganded AhR and HIF-1 α should be minimal – that is, no AhR ligand was used and accumulation of the HIF-1 α protein was not triggered in normoxic MCF-7 cells which were used for all Ainp2 studies. AhR does not seem to contribute to the Ainp2 effect since α -naphthoflavone, which is an AhR antagonist, had no effect on the E2-activated, ERE-driven luciferase expression regardless of the presence or absence of Ainp2. However, this Ainp2 suppression on the ER signaling appears to be Arnt-mediated because (1) Ainp2 suppressed the Arnt-dependent luciferase activity; (2) the E2-activated *GREB1* expression, which should be Arnt-dependent, was also suppressed significantly by Ainp2; (3) Ainp2 had no effect on the ERE-driven *pS2* expression, which appeared to be not an Arnt-dependent event in MCF-7 cells; (4) Ainp2 interacted with Arnt but not ER α and ER β ; (5) Ainp2 suppressed the interaction between ER α and Arnt; (6) Ainp2 suppressed the recruitment of Arnt to the ERE3 region of the *GREB1* promoter and (7) Ainp2 did not affect the luciferase activity in the Arnt-knockdown cells. Collectively, these observations strongly supported that Arnt is essential for the Ainp2 suppression of the ER function in MCF-7 cells.

Although the Ainp2 cDNA sequence was isolated from a human liver cDNA library, we could not detect its message in two human hepatoma cells (HepG2 and Hep3B). We were unable to detect the Ainp2 protein in primary human hepatocytes (BD Biosciences, San Jose, CA) (data not shown). However, the Ainp2 protein was detected in human fetal and adult liver extracts (BD Biosciences, San Jose, CA) (Fig. 6), suggesting that Ainp2 is expressed in normal liver but its expression may be sensitive to the carcinogenic process and in vitro manipulations. We know that Ainp2 can be post-translationally modified since our baculovirus expressed Ainp2 has an additional band at around 25 kDa and the transfected Ainp2 in MCF-7 cells is larger than the bacterially expressed Ainp2 [7]. Therefore, different sizes of the Ainp2 protein observed in different extracts could be due to the cell-specific post-translational modifications. There were multiple bands in the Jurkat extracts; we believe that the top band is Ainp2 since this band was absent when the Ainp2 antibodies were pre-cleared with the bacterially expressed Ainp2 before the Western blot analysis [7]. Although the endogenous function of Ainp2 is unclear, the cellular Ainp2 function is likely to be Arnt-dependent since it interacts with Arnt. We do not expect that Ainp2 plays any role in the ER signaling in MCF-7 cells since we were not able to detect the Ainp2 protein in the MCF-7 extract (Fig. 6).

The idea that the ER signaling can be affected by an Arnt-interacting molecule such as Ainp2 is certainly intriguing. Currently




Fig. 6. Chemiluminescent (Lumi-Phos) Western analysis showing the expression of Ainp2 in Jurkat and human liver extracts. Lane 1, Jurkat soluble extract (40 μ g); lane 2, bacterially expressed purified 6His-Ainp2 (1 μ g); lane 3, human fetal liver extract (10 μ g); lane 4, human adult liver extract (10 μ g); lane 5, MCF-7 soluble extract (40 μ g). Arrows indicate the Ainp2 protein. The minor (lower) band in lane 3 could be the unmodified Ainp2. Samples were separated on a 15% tricine SDS–PAGE gel and the chicken Ainp2 C634FB (1:500), which was generated using the bacterially expressed 6His-Ainp2 as the antigen, was used as the primary antibodies.

about 70% of women with breast cancer are ER-positive and these women most likely take either the ER α antagonist tamoxifen or the aromatase inhibitor letrozole as an adjuvant therapy after mastectomy [35,36]. Realizing that both agents suppress the ER signaling primarily by reducing the binding of estrogen to ER and letrozole in particular appears to be less tolerable when taken chronically [37], the Arnt-mediated mechanism in suppressing the ER signaling is an appealing alternative for the treatment of breast cancer. Additionally, GREB1 has been reported to be one of the few genes that mediate the estrogen-dependent breast cancer growth in cell culture [38]. Thus, a strategy of using Ainp2 (or an Arnt-interacting peptide) to suppress the GREB1 gene expression is certainly a novel approach to treat the ER-positive breast cancer. Although some reports suggested that abnormal Arnt protein either in the form of the fusion protein TEL-Arnt [39] or the splice variants [40] may contribute to tumorigenesis by possibly inhibiting apoptosis mediated by the hypoxia signaling pathway [41], the underlying mechanisms and the precise role of Arnt in cancers are poorly understood and should be investigated extensively. Here we have shown evidence that this Arnt-mediated approach works and should allow us to rationally screen molecules that bind to Arnt for inhibitors of the ER signaling.

Acknowledgments

We thank Dr. Jesika Faridi (University of the Pacific) for providing the pVit-ERE-Luc plasmid, Dr. Roshanak Rahimian (University of the Pacific) for the pAC_{sk12}CMV5-ER α and pAC_{sk12}CMV5-ER β plasmids, and Dr. Chris Bradfield (McArdle Cancer Lab) for the pSport-Arnt plasmid. This work is supported by a grant from the National Institutes of Health (R01 ES014050).

References

- [1] Q. Ma, Curr. Drug Metab. 2 (2001) 149–164.
- [2] C. Blancher, A.L. Harris, Cancer Metastasis Rev. 17 (1998) 187–194.
- [3] D.W. Nebert, T.P. Dalton, A.B. Okey, F.J. Gonzalez, J. Biol. Chem. 279 (2004) 23847–23850.
- [4] J.A. Forsythe, B.H. Jiang, N.V. Iyer, F. Agani, S.W. Leung, R.D. Koos, G.L. Semenza, Mol. Cell. Biol. 16 (1996) 4604–4613.
- [5] G.L. Wang, G.L. Semenza, Curr. Opin. Hematol. 3 (1996) 156–162.
- [6] G.L. Semenza, Biochem. Pharmacol. 59 (2000) 47–53.
- [7] Y. Li, T.C. Luu, W. Chan, Arch. Biochem. Biophys. 441 (2005) 84–95.
- [8] B.W. O'Malley, M.J. Tsai, Biol. Reprod. 46 (1992) 163–167.
- [9] G.K. Whitfield, P.W. Jurutka, C.A. Haussler, M.R. Haussler, J. Cell. Biochem. Suppl. (1999) 110–122.
- [10] T. Barkhem, L.A. Haldosen, J.A. Gustafsson, S. Nilsson, Mol. Endocrinol. 16 (2002) 2571–2581.
- [11] M.G. Ghosh, D.A. Thompson, R.J. Weigel, Cancer Res. 60 (2000) 6367–6375.
- [12] C.H. Lee, A.M. Edwards, Carcinogenesis 22 (2001) 1473–1481.
- [13] H. Watanabe, E. Takahashi, M. Kobayashi, M. Goto, A. Krust, P. Chambon, T. Iguchi, J. Mol. Endocrinol. 36 (2006) 81–89.
- [14] K.M. Waters, S. Safe, K.W. Gaido, Toxicol. Sci. 63 (2001) 47–56.
- [15] J.M. Beekman, G.F. Allan, S.Y. Tsai, M.J. Tsai, B.W. O'Malley, Mol. Endocrinol. 7 (1993) 1266–1274.
- [16] H. Chen, R.J. Lin, W. Xie, D. Wilpitz, R.M. Evans, Cell 98 (1999) 675–686.
- [17] M.Y. Kim, S.J. Hsiao, W.L. Kraus, EMBO J. 20 (2001) 6084–6094.
- [18] S. Karmakar, E.A. Foster, C.L. Smith, Endocrinology 150 (2009) 1588–1596.
- [19] Y. Zhu, C. Qi, S. Jain, M.M. Le Beau, R. Espinosa 3rd, G.B. Atkins, M.A. Lazar, A.V. Yeldandi, M.S. Rao, J.K. Reddy, Proc. Natl. Acad. Sci. USA 96 (1999) 10848–10853.
- [20] K.W. Jeong, Y.H. Lee, M.R. Stallcup, J. Biol. Chem. 284 (2009) 29298–29309.
- [21] R. Clarke, T. Skaar, K. Baumann, F. Leonessa, M. James, J. Lippman, E.W. Thompson, C. Freter, N. Brunner, Breast Cancer Res. Treat. 31 (1994) 237–248.
- [22] M.P. McCafferty, R.E. McNeill, N. Miller, M.J. Kerin, Breast Cancer Res. Treat. 116 (2009) 425–432.
- [23] S. Safe, M. Wormke, I. Samudio, J. Mammary, Gland Biol. Neoplasia 5 (2000) 295–306.
- [24] F. Ohtake, K. Takeyama, T. Matsumoto, H. Kitagawa, Y. Yamamoto, K. Nohara, C. Tohyama, A. Krust, J. Mimura, P. Chambon, J. Yanagisawa, Y. Fujii-Kuriyama, S. Kato, Nature 423 (2003) 545–550.
- [25] J.M. Shipley, D.J. Waxman, Toxicol. Appl. Pharmacol. 213 (2006) 87–97.
- [26] M. Abdelrahim, E. Ariazi, K. Kim, S. Khan, R. Barhoumi, R. Burghardt, S. Liu, D. Hill, R. Finnell, B. Wlodarczyk, V.C. Jordan, S. Safe, Cancer Res. 66 (2006) 2459–2467.
- [27] B.E. Gillesby, M. Stanostefano, W. Porter, S. Safe, Z.F. Wu, T.R. Zacharewski, Biochemistry 36 (1997) 6080–6089.
- [28] S. Brunnberg, K. Pettersson, E. Rydin, J. Matthews, A. Hanberg, I. Pongratz, Proc. Natl. Acad. Sci. USA 100 (2003) 6517–6522.
- [29] C.L. Partch, P.B. Card, C.A. Amezcua, K.H. Gardner, J. Biol. Chem. 284 (2009) 15184–15192.
- [30] K.K. Graven, Q. Yu, D. Pan, J.S. Roncarati, H.W. Farber, Biochim. Biophys. Acta 1447 (1999) 208–218.
- [31] J. Sun, Z. Nawaz, J.M. Slingerland, Mol. Endocrinol. 21 (2007) 2651–2662.
- [32] J. Ruegg, E. Swedenborg, D. Wahlstrom, A. Escande, P. Balaguer, K. Pettersson, I. Pongratz, Mol. Endocrinol. 22 (2008) 304–316.
- [33] R.S. Pollenz, N.A. Davarinos, T.P. Shearer, Mol. Pharmacol. 56 (1999) 1127–1137.
- [34] F. Ohtake, A. Babe, I. Takada, M. Okada, K. Iwasaki, H. Miki, S. Takahashi, A. Kouzmenko, K. Nohara, T. Chiba, Y. Fujii-Kuriyama, S. Kato, Nature 446 (2007) 562–566.
- [35] P.E. Goss, J.N. Ingle, S. Martino, N.J. Robert, H.B. Muss, M.J. Piccart, M. Castiglione, D. Tu, L.E. Shepherd, K.I. Pritchard, R.B. Livingston, N.E. Davidson, L. Norton, E.A. Perez, J.S. Abrams, P. Therasse, M.J. Palmer, J.L. Pater, N. Engl. J. Med. 349 (2003) 1793–1802.
- [36] P.A. Ganz, Am. J. Med. 118 (2005) 136–141.
- [37] C. Fontaine, A. Meulemans, M. Huizing, C. Collen, L. Kaufman, J. De Mey, C. Bourgain, G. Verfaillie, J. Lamote, R. Sacre, D. Schallier, B. Neyns, J. Vermorken, J. De Greve, Breast 17 (2008) 376–381.
- [38] J.M. Rae, M.D. Johnson, J.O. Scheys, K.E. Cordero, J.M. Larios, M.E. Lippman, Breast Cancer Res. Treat. 92 (2005) 141–149.
- [39] F. Salomon-Nguyen, V. Della-Valle, M. Mauchauffe, M. Busson-Le Coniat, J. Ghysdael, R. Berger, O.A. Bernard, Proc. Natl. Acad. Sci. USA 97 (2000) 6757–6762.
- [40] C. Qin, C. Wilson, C. Blancher, M. Taylor, S. Safe, A.L. Harris, Clin. Cancer Res. 7 (2001) 818–823.
- [41] P. Carmeliet, Y. Dor, J.M. Herbert, D. Fukumura, K. Brusselmans, M. Dewerchin, M. Neeman, F. Bono, R. Abramovitch, P. Maxwell, C.J. Koch, P. Ratcliffe, L. Moons, R.K. Jain, D. Collen, E. Keshert, Nature 394 (1998) 485–490.